STOCKS TELEGRAPH

Author: ST Staff

  • Why does Pinduoduo Inc. (PDD) stock fall in Pre-Market trading?

    Why does Pinduoduo Inc. (PDD) stock fall in Pre-Market trading?

    Pinduoduo Inc. (PDD) is an eCommerce mobile-based platform in china that offers a wide range of products of daily life. Despite the positive unaudited fourth quarter and fiscal year 2020 financial results announced by Pinduoduo Inc. (PDD), PPD stock fell on Wednesday’s pre-market trading as PDD stock price was down by 6.36% to drop at $150.65 a share at the time of this writing. At the previous closing, PDD stock was up by 1.11% with a $160.89 per share price. Let’s understand deeply the current happenings.

    Fourth-quarter highlights

    • PPD stock generated RMB26,547.7 revenue in the fourth quarter which is 146% higher than the MB10,792.7 million in the same quarter of last year.
    • Pinduoduo stock suffered RMB11,526.1 million cost of revenue in the fourth quarter of 2020 representing a 466% increase as compared to the same tenure in the previous year.
    • Operating expenses reached MB17,069.4 million as compared to RMB10,890.6 million in the same quarter of the prior year.

    The fiscal Year 2020 highlights

    • PPD stock revenue surged to RMB59,491.9 million with 97% growth as compared to the RMB30,141.9 million revenue of last year.
    • The total cost of revenues reached RMB19,278.6 million which shows a 204% increase over the year.
    • Total Operating expenses reached RMB49,593.5 million as compared to RMB32,341.3 million of last year.

    PDD stock to promote digital inclusion in Agriculture Sector.

    Pinduoduo stock is focused on the development of the agriculture sector in China. PDD held live streaming session in the miserable days of COVID-19 to promote the agriculture products of farmers and launched the “Help the Farmers” channel to help farming communities. This new method of promoting agriculture products has risen the demand for new roles with different skills thus creating new opportunities for individuals committed to the agriculture sector. PDD has prepared more than 100,000 new farmers to operate the eCommerce business and plans to train 100,000 more new farmers to meet the eCommerce business requirements.

    Colin Huang steps down from His role.

    PDD also announced today that its founder Colin Huang will step back from the board of directors effective today to focus on the research in food and life sciences in order to devise long-term strategies for the Pinduoduo stock. Huang will not sell his shares for a further three years.

    Conclusion:

    Though PDD stock released the earnings report that has beaten the revenue estimates PDD stock price is still down in the pre-market. This is something confusing for investors but it’s a fact that the stock market is unpredictable. For long terms prospects, the PDD stock can be a good bet for investors due to its expansion and digitization in the agriculture sector. Hence investors are required to do a lot of homework before taking any decision.

  • Strata Skin Sciences Inc. (SSKN) stock is fluctuating. Here’s what has happened?

    Strata Skin Sciences Inc. (SSKN) stock is fluctuating. Here’s what has happened?

    Strata Skin Sciences Inc. (NASDAQ: SSKN) stock declined by 5.50% in the last trading close while the SSKN stock rises by 21.16% during pre-market. Strata Skin Sciences is a medical technology company in dermatology and plastic surgery that focuses on designing, developing, and commercializing non-invasive tools to give additional information to the dermatologist during melanoma skin examinations.

    Recent Developments in SSKN

    • On 16 March, Strata Skin Sciences announced that the company is set to participate in an upcoming Lytham Partners Spring 2021 Investor Conference happening on March 30, 2020.
    • Another positive development for SSKN is that their independent study on the treatment of vitiligo Company’s XTRAC excimer laser got published in the Journal of The Euorpeon Academy of Dermatology and Venereology in the November 2020 issue.  For this, the study was done by a team of dermatologists in Japan and was approved by the Ethics Committee of Kansai Medical University Kori Hospital.

    According to the findings of the study, patients with refractory vitiligo including those who were previously unresponsive to traditional therapies such as topical steroids, excimer light, and narrowband UVB light achieved adequate repigmentation in five treatments. These patients were treated with the XTRAC excimer laser under a reduced blistering dose regimen, which offered greater therapeutic outcomes with less treatments than other UVB phototherapies.

    The higher irradiation rate of XTRAC relative to other available UVB phototherapies, ascribed better patient results in the research. Furthermore, the XTRAC treatments were well tolerated, and the use of a low blistering dose was shown to minimize the amount of treatment sessions required, easing the burden on patients and medical staff.

    Conclusion

    These recent developments in Strata Skin Sciences is visibly the reason behind the up and down in SSKN stock price. Investors seem to be interested in buying SSKN stock but it is clear that they are also being careful in making any long-term commitment.

  • SAVARA Inc. (SVRA) stock is soaring high by 12.68%. Let’s find out why?

    SAVARA Inc. (NASDAQ: SVRA) stock jumped high in the last trading, close by 15.82%, whereas the SVRA stock rises by 12.68% during the pre-market after announcing the closing of a $130 million public offering. SVRA is a pharmaceutical orphan lung disease company that deals with the development of efficient therapies to treat severe or life-threatening rare respiratory diseases. Currently, molgramostim is its lead program in its phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). SAVARA has its expertise in orphan drug development and pulmonary medicine to fulfill the unmet requirements.

    What is happening?

    SAVARA Inc. has today announced the completion of its previously announced underwritten public offering of 57,479,978 shares of its common stock, including 11,694,150 shares sold after the underwriters exercised their option to buy additional shares, at a public offering price of $1.45 per share.

    The net capital generated from this offering will be used to support SAVARA’s operations, including clinical research, production, regulatory, and commercial activities related to its molgramostim nebulizer solution (molgramostim, formerly known as Molgradex) in autoimmune pulmonary alveolar proteinosis (aPAP) program. The capital will also be used to support the IMPALA 2 trial and fulfill the general and administrative expenses.

    Other Recent Developments

    • Another positive development follows the rise in SVRA stock price: Piper Sandler initiated coverage on the stock with an overweight rating and a price target of $7 per share.
    • Also, the insiders are continuously buying the SVRA stock; the most recent insider purchase was by Director Ramsay, who has bought 689,655 shares in SVRA for $1,000,000. This has doubled his share count to 811,797 shares
  • TD Holdings, Inc. (GLG) stock is getting high in Pre-Market trading: What’s going on?

    TD Holdings, Inc. (GLG) stock is getting high in Pre-Market trading: What’s going on?

    Shares of TD Holdings, Inc. (GLG) were getting high in Wednesday’s pre-market trading amid the spread of news that GLG and its wholly-owned subsidiary Tongdow E-Trade Limited has signed the letter of intent with Chenzhou Dingmei Silver Co., Ltd to get the ownership of molybdenum copper ore in Kazakhstan. GLG stock price saw a jump of 14.80% to reach $2.25 a share as of this writing. GLG stock was up by 10.11% at the previous closing. Let’s understand more about the penny stock.

    TD Holdings to become the owner of molybdenum copper ore in Kazakhstan.

    TD Holdings, Inc. (GLG) mainly focuses on the new commodities trading business in the People’s Republic of China.GLG has signed the letter of intent pursuant to which the Chenzhou Dingmei will sell 100% molybdenum copper ore mine located in Kazakhstan to TD Holdings.GLG and Tongdow E-Trade will have the complete equity ownership of East Kazakhstan Group Company mentioned in the letter. An aggregate consideration of RMB 98 million in the form of shares and cash has been decided for this deal. The transaction will proceed after the formal procedures done by the relevant parties to avoid legislative complications.

    Past Happenings

    On March 10, 2021, GLG stock announced the warrant exercise agreement according to which recognized investors are willing to exercise all the outstanding warrants without cash to buy an aggregate of 100,000 and an aggregate of 1,530,000 common shares, which GLG stock issued on May 23, 2019, and April 15, 2019, respectively.

    On February 25, 2021, Hainan Jianchi Import and Export Co., Ltd, a GLGwholly-owned subsidiary, was granted the license of Dangerous Chemicals Business by the State Administration of Work Safety of China. This license will make GLG expand its strategic business in the energy commodities field and provide commodities services to clients in the chemical energy areas.

    So Now:

    The penny GLG stock is continuing the bullish trend in the stock market.GLG stock has been much in the news for the past few weeks. Recent GLG stock news suggests that TD Holdings is growing and expanding its network day by day. In short, GLG stock is progressing and can be a good bet for investors. Still, it’s a good practice to analyze the balance sheet, company’s fundamentals, and growth prospects before adding any stock to the portfolio.

  • What’s the latest about Nabriva Therapeutics (NBRV)?

    What’s the latest about Nabriva Therapeutics (NBRV)?

    Nabriva Therapeutics (NBRV) stock is surging in the pre-market on Wednesday, March 17, 2021. It has gained 17.19% as of this writing. The stock went down 8.57% on Tuesday, March 16, 2021.

    Latest Development

    On March 16, 2021,Nabriva Therapeutics announced its results from a post-hoc analysis of clinical data from the pivotal Lefamulin Evaluation Against Pneumonia (LEAP) 2 Phase 3 clinical trial has been published in The Journal of Emergency Medicine 

    The trial results revealed that the patients avoided hospitalization by taking XENLETA for 5 days. XENLETA was demonstrated in patients with moderate to severe community-acquired bacterial pneumonia (CABP). XENTLETA was approved by the FDA in August 2019 and the first IV and oral antibiotic with a novel mechanism of action approved by the FDA in nearly two decades.

    Recent Financial results

    On March 12, 2021, NBRV announced its financial results for the fourth quarter and the year ended December 31, 2020.

    Q4 Financial Highlights

    • NBRV revenue for the reported quarter was $2.5 million.
    • Research and development expenses were $2.8 million
    • Selling, general and administrative expense were $17.5 million

    Full-year Financial Highlights

    • NBRV revenue for the full-year 2020 was $5.0 million.
    • Research and development expenses were $15.1 million for the full year.
    • Selling, general and administrative expense were $55.3 million.
    • Nabriva had $41.4 million in cash and cash equivalents as of December 31 2020.

    NBRV Corporate Updates

    • On March 10, 2021, Steven Gelone, Pharm D, was selected by Nabriva’s Board as a new member to the board effective immediately.
    • On February 26, 2021, Daniel Dolan was appointed as Chief Financial Officer, he started working as CFO on March 13.

    NBRV Business Updates

    On March 1, 2021, Nabriva signed an agreement with investors for the purchase and sale of ordinary sharesfor aggregate net proceeds of $23.4 million.

    About NBRV

    Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. The company was founded in 2005 and is based in Ireland.

    The NBRV latest product XENLETAreceived U.S. Food and Drug Administration approval to treat CABP. The company is also working on also developing CONTEPO to treat urinary tract infections (cUTI), including acute pyelonephritis.

  • Surgalign Holdings Inc. (SRGA) stock plummeted more after poor financial results announced

    Surgalign Holdings Inc. (SRGA) stock plummeted more after poor financial results announced

    Surgalign Holdings Inc. (SRGA) stock plummeted on Tuesday, March 16, 2021. SRGA lost 3.83% in the normal trading session and it further went down by 13.94% in the after-hours trading. SRGA stock announced its financial results for the fourth quarter and full-year 2020, yesterday March 16 which push the stock towards negativity.

    Financial Highlights for the fourth quarter of 2020

    • SRGA revenue was $26.2 million for the quarter ended December 31, 2020, compared to $31.6 million for the prior-year period.
    • SRGA’s Gross profit for the fourth quarter of 2020 was $12.8 million.
    • Surgalign Holdings spent $27.3 million in Marketing, general and administrative expenses in the reported quarter compared to $39.9 million same quarter in 2019.
    • R&D expense for the fourth quarter of 2020 was $2.2 million compared to $4.4 million in the prior-year period.
    • Adjusted EBITDA was a $7.7 million loss for the reported quarter compared to a $14.3 million loss in the prior-year period.
    • SRGA suffered a Net loss of $118.1 million from continuing operations for the fourth quarter of 2020 compared to $199.6 million for the fourth quarter of 2019.
    • SRGA had approximately $44 million in cash as of December 31, 2020.

    Commercial Launch of ViBone® Moldable and the First Clinical Implantation

    On January 12, 2021, SRGA announced the commercial launch and the completion of the first surgery of ViBone Moldable in the US. Dr. Adam Crowl completed the first implantation at OrthoVirgina in Midlothian, VA.ViBone Moldable is a next-generation viable cell bone matrix optimized to protect and preserve the health of native bone cells to potentially enhance new bone formation.

    Conclusion

    If we see in the past, SRGA is facing tough times, and over three years, the share price is down 53%. In the recent past, it dropped 34% in the last year. According to analyst predictions, SRGA needs at least 3 years more to turn things around and to make a profit.

  • The Renewable Energy Group Inc. (REGI) stock declines sharply. Why is it so?

    The Renewable Energy Group Inc. (REGI) stock declines sharply. Why is it so?

    Renewable Energy Group Inc. (NASDAQ: REGI) stock declined by 4.96% in the last trading close, whereas the REGI stock price falls by 6.82% during pre-market after Pomerantz law firm on March 16 announced the case filed against Renewable energy group and its certain officials. REGI is a biodiesel company that provides clean, low carbon transportation fuels. REGI is the largest producer of advanced biofuels with 13 biorefineries and a feedstock processing facility.

    What is happening?

    As per the recent news, the class action docketed under 21-cv-02244 is filed on behalf of people except for the Defendants, who purchased or acquired Renewable Energy securities between May 3, 2018, February 25, 2021, inclusive (the “Class Period”). The claims are made against the Defendants under the Securities Exchange Act of 1934. The Defendants are accused of making materially false statements, and also they failed to reveal material adverse facts about REGI’s business, operations, and prospects. Following are the major accusations made against Defendants:

    • The Defendants of REGI did not inform the people that petroleum diesel was not periodically added to Renewable Energy Group’s specific loads. Still, instead, it was added by the REGI customers due to the failure in the diesel addictive system.
    • As a result of the above-mentioned point, Renewable Energy was not the proper claimant of certain BTC payments on Biodiesel that it sold between January 1, 2017 and September 30, 2020.
    • Renewable Energy Group is also accused of stating wrong figures of revenue and net income for certain periods.
    • Also that REGI’s internal control over financial statements had a material weakness related to the purchase and use of petroleum diesel gallons when blending with biodiesel.
    • Lastly, the Renewable Energy Group Defendants’optimistic claims about REGI’s business, activities, and prospects were materially misleading.

    Effect of Fourth Quarter and full year 2020 financial results

    Renewable Energy Group, On February 25, announced its fourth quarter and full-year 2020 financial results in which REGI disclosed that they would restate $38.2 million in cumulative revenue from January 2018 through September 30, 2020, because REGI was not the justified claimant for certain BTC payments on biodiesel it sold between the time span of January 1, 2017, to September 30, 2020. After this news broke, the REGI stock price fell $8.17, or 9.5%, in two consecutive trading sessions to close at $77.77 per share on February 26, 2021. This has given a significant setback to REGI wherein the investors do not find it a sensible step to investing in REGI stock.

  • Here is why the Anchiano Therapeutics Ltd. (ANCN) stock has soared

    Here is why the Anchiano Therapeutics Ltd. (ANCN) stock has soared

    Anchiano Therapeutics Ltd. (NASDAQ: ANCN) stock soared by 5.37% to the current price of $4.71.

    ANCN has finally merged with Chemomab Ltd.

    The reason for this price increase can correlate with the much-anticipated news of the delayed merger between the two Israeli-based companies. The merger took place on the 15th of March, as was announced by Anchiano Therapeutics Ltd. (ANCN) by sending invitation letters to shareholders about the special meeting to approve the merger.

    Why ANCN stock news did not fare well in the past

    Anchiano Therapeutics Ltd (ANCN) has been developing major news in the past, but the report did not sustain its hype and kept dying out. One of the reasons is because the merger was expected to proceed earlier into the year 2021, and before the merger, the biotech company released news about initial trials of cancer research which were then discontinued in the second phase. The reason so is because the data analysis of treatment through gene therapy suggested that the treatment of bladder cancer had very little probability of complete responses in the patients

    What’s the next plan of action after the merger?

    Now that the merger has taken place, the 16-year old company, AnchianoTherapeutics Ltd (ANCN), will switch its trade ticker to “CMMB” and its public company name to Chemomab Therapeutics Ltd. After this merger, Chemomab Ltd would become the majority holder of the merged company. They will focus on the PIPE financing to advance CM-101 into Phase 2 clinical trials in rare fibrotic indications.

    The news that indicates to support this financing is that the merged companies have also announced a private investment of $45.5 million. This personal investment is a combination of original and new investors who now see hope in the ANCN’s positive stock movement.

    When we look at the details of the financing, it indicates the sale of 41,908,232 ADSs. The warrants that accompany these shares are more than 4 million (4,190,819 to be precise). The penny-stock price at which they were sold is $1.08433 per share, which is also the warrant’s exercise price. One thing to note here is that the pre-reverse split will take effect immediately before the merger’s closing.

    Why are CM 101 phase-2 trials significant?

    Furthermore, the merged-company can now focus on the trial inceptions for CM 101. CM 101 phase 2 trials will focus on orphan indications of inflammatory-fibrotic diseases. This is significant for investors from the point-of-view of being that the specific diseases targeted in this trial are sclerosing cholangitis (PSC) and systemic sclerosis both damage multiple organs, and both have unmet needs with the patients suffering from debilitating pain due to no FDA-approved diseases.

     Positive news of the success of the phase2 trial can lead to the possibility of FDA approval, which will correspond to a substantial uplift in the stock-movement of the then-merged Chemomab Therapeutics Ltd.

  • Here’s why Bioceres Crop Solutions Corp. (BIOX) stock is getting a lot of hype

    Here’s why Bioceres Crop Solutions Corp. (BIOX) stock is getting a lot of hype

    Bioceres Crop Solutions Corp. (AMEX: BIOX) stock soared today by a percentage of 11.33% to the current price of $11.10. The BIOX stock previously closed at $9.97.

    BIOX has now acquired Moolex

    The soar in the BIOX stock price comes with the news of BIOX entering into definitive agreements to acquire a 6% ownership interest in the Molecular Farming Company called Moolec Science Ltd.

    To understand how significant this acquisition between both companies is, we need to look at the background of what each of the two biotech companies does.

    BIOX provides innovative crop productivity solutions and carbon-neutral designs

    Bioceres Crop Solutions Corp. (BIOX) is a biotech crop company that provides productivity technologies to enhance crop production while leaning towards a carbon-neutral design. BIOX does this in a unique, innovative way that creates economic incentives for farmers and agricultural stakeholders to adopt an environmentally friendlier production practice. BIOX’s design and technologies are all patented for their unique innovations, which consist of seeds, microbial agricultural inputs, crop protection solutions, and next-generation crop nutrition.

    Moolec excels at substituting animal-based protein with plant-based protein

    Moolec Science is a Food-tech company with its own unique set of patented technology designs and solutions in its pipeline. Essentially what Moolec does is that hybridizes plant-based and cell-based technology for the production of animal-free food solutions. This is a similar concept to the invention of the “Impossible Burger” by equal food-tech company called Impossible Foods. Moolec has several breakthrough developments of its own. The team has created the first-ever functional protein, namely- bovine chymosin in plants (safflower) through Molecular Farming.

    Here’s why this merger is significant

    Moolec science’s business model is based on the scalability of a plant-based production system while combining it with cellular agriculture’s practical functionality. Together this produces an efficient substitute as animal-free solutions at a much lower cost than the existing technologies.

    In its pipeline, Moolec has set its sight on developing and replacing other animal proteins by using plant-based crops such as soybeans, peas, oat, and wheat which can then be formulated into sustainable hybrid meat, dairy, and egg replacements.

    The worldwide alternative proteins market is rapidly growing and expanding as the competitors and technology usage in this sector advances. More and more people are becoming conscious about animal-based products, and awareness of the alternates is becoming popular in consumer demand. The market valuation of animal-alternative proteins reached USD 14.95 billion in 2019, and this is projected to grow significantly by 2025.

    BIOX has made the smart move to seize this hype train during its inception period, which will allow it to grab a decent market share in this fast-growing industry as well as broaden its company’s strategy of transitioning towards carbon neutrality.

  • Here’s what to look out for if you want to invest in Onconova Thereapeutics Inc. (ONTX) stock

    Here’s what to look out for if you want to invest in Onconova Thereapeutics Inc. (ONTX) stock

    The Onconova Thereapeutics Inc. (NASDAQ: ONTX) stock fell by -4.46% to the current price of $1.07. The ONTX stock previously closed at $1.12.

    ONTX Full Year 2020 report has mixed news

    There seems to be no exact press news with the last 24-hours that could explain the plunge in the ONTX stock movement. However, ONTX did release its Full Year 2020 financial results report on March 12. While the fourth quarter of 2020 in the report did highlight positive news related to clinical and trial approvals, the financials of the entire year did have some shaky prospects.

    Let’s look at the good news first. FDA approved the clearance of the ON 123300to begin its 1st phase trial. ON 123300 also received approval by IRB at one US trial site. Phase 1 of the ON 123300 solid tumor study is ongoing and enrolling patients. An investigator-initiated study with oral rigosertib in advanced KRAS mutated non-small cell lung cancer is also persistent.

    The financial results have questionable prospects

    However, when it comes to the financial results of the report, we see that the cash and cash equivalents as of December 31, 2020, were $19.0 million, which is $3.7 million less than December 31, 2019financials. Net loss for 2020 was $25.2 million which is greater than the $21.5 million loss in 2019. General and administrative expenses were $8.3 million for both years, which shows consistency as lower personnel stock compensation due to personnel reductions in 2019 were offset by corporate legal and stockholder meeting expenses.

    Research and development expenses were $16.9 million for 2020 compared with $15.5 million for 2019, while ONTX stock raised net proceeds of $35.2 million from two equity offerings with institutional investors.

    What you need to understand about ONTX

    Investors like to identify the Biotech stock ONTX as an attractive stock to keep an eye on. However, with such penny stocks, no matter what fluctuations and volatility it reacts to, the fundamentals of the company are relatively a solid point of analysis to look at before investing in it. The first fundamental thing to look at for the ONTX is its balance sheet. Suppose the current status of the balance sheet is healthy. In that case, it determines that ONTX can carry out all its financial and non-financial obligations while adhering to the investor’s interest.

    Another factor to keep in mind while deciding to buy ONTX stock is that the importance of the stock movement trend far outweighs the outlook of ONTX.